VolitionRX (NYSEAMERICAN:VNRX) Issues Earnings Results

VolitionRX (NYSEAMERICAN:VNRX) released its quarterly earnings results on Thursday. The medical research company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.27), FiscalAI reports. The business had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.52 million.

VolitionRX Stock Down 9.1%

Shares of NYSEAMERICAN VNRX traded down $0.20 during midday trading on Friday, reaching $2.00. The company had a trading volume of 173,571 shares, compared to its average volume of 262,094. The firm’s fifty day moving average price is $3.31 and its 200-day moving average price is $4.96. VolitionRX has a one year low of $2.00 and a one year high of $18.80. The stock has a market cap of $16.66 million, a PE ratio of -0.48 and a beta of 1.03.

Hedge Funds Weigh In On VolitionRX

Several hedge funds and other institutional investors have recently modified their holdings of the company. Armistice Capital LLC increased its position in shares of VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after buying an additional 887,351 shares during the period. Geode Capital Management LLC raised its holdings in VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after purchasing an additional 85,816 shares in the last quarter. Citadel Advisors LLC lifted its position in VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after buying an additional 135,775 shares during the period. Squarepoint Ops LLC bought a new stake in shares of VolitionRX during the 4th quarter valued at $34,000. Finally, Jane Street Group LLC bought a new stake in VolitionRX during the fourth quarter worth about $28,000. 8.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on VNRX. D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. Citigroup lowered shares of VolitionRX to a “hold” rating in a research report on Monday, April 20th. Finally, HC Wainwright reduced their target price on VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, VolitionRX presently has a consensus rating of “Moderate Buy” and an average price target of $46.67.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.